Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C.
DAA
SVR
liver stiffness
magnetic resonance elastography
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
17
08
2020
received:
13
06
2020
accepted:
01
09
2020
pubmed:
6
9
2020
medline:
9
10
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Almost all patients achieved sustained virological response (SVR) by direct-acting antivirals (DAA) therapy, but it is not clear as to what extent DAA therapy affects changes in liver fibrosis after achieving SVR. In this study, we investigated the changes of liver stiffness by magnetic resonance elastogaraphy (MRE) during DAA therapy. A total of 308 patients were enrolled in the study. Liver stiffness was measured twice before and after DAA treatment using MRE and time-course change of liver stiffness was investigated. The median (interquartile range) values for liver stiffness were 4.2 (3.2-6.1) kPa at baseline and 3.3 (2.6-4.8) kPa at SVR, demonstrating a significant improvement (p < .01). A total of 44% of patients had no improvement in liver stiffness despite achieving SVR. In patients with advanced fibrosis (lower level of albumin [Alb] or histological fibrosis stage F4), it was difficult to improve liver stiffness. Except for Alb, there were no blood tests associated with nonimprovement in liver stiffness, making these cases difficult to predict. In conclusion, despite obtaining SVR, improvement in liver stiffness could not be obtained in some cases, especially in patients with advanced fibrosis. In these patients, liver stiffness must be followed even if SVR is obtained.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3744-3751Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Lim SG, Aghemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet. Gastroenterol Hepatol. 2017;2:52-62.
Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.
Hayashi T, Tamaki N, Kurosaki M, et al. Use of the serum Wisteria floribunda agglutinin-positive Mac2 binding protein as a marker of gastroesophageal varices and liver-related events in chronic hepatitis C patients. Diagnostics (Basel). 2020;10:10.
The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in. a modelling study. Lancet Gastroenterol Hepatol. 2015;2017(2):161-176.
Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterol. 2014;146:1176-1192.
Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292.
Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-S172.
Standish RA. An appraisal of the histopathological assessment of liver fibrosis. Gut. 2006;55:569-578.
Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15-20.
Asrani SK. Incorporation of noninvasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol. 2015;13:2190-2204.
Chen X, Wen H, Zhang X, et al. Development of a simple noninvasive model to predict significant fibrosis in patients with chronic hepatitis B: combination of ultrasound elastography, serum biomarkers, and individual characteristics. Clin Transl Gastroenterol. 2017;8:e84.
Yada N, Tamaki N, Koizumi Y, et al. Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease. Dig Dis. 2017;35:515-520.
Lefebvre T, Wartelle-Bladou C, Wong P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. Eur Radiol. 2019;29:6477-6488.
Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152:598-607.e2.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
Sato S, Genda T, Ichida T, et al. Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutinin-positive Mac-2-binding protein. Int J Mol Sci. 2016;17:17.
Yasui Y, Abe T, Kurosaki M, et al. Elastin fiber accumulation in liver correlates with the development of hepatocellular carcinoma. PLoS One. 2016;11:e0154558.
Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70:133-141.
Ajmera VH, Liu A, Singh S, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020;71:849-860.
Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239-1250.
Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549-559.
Tamaki N, Higuchi M, Kurosaki M, et al. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. J Viral Hepat. 2019;26:893-899.
Higuchi M, Tamaki N, Kurosaki M, et al. Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography. Clin Gastroenterol Hepatol. 2019;17:2616-2618.
Tamaki N, Kurosaki M, Tanaka K, et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat. 2013;20:72-76.
Tamaki N, Kurosaki M, Matsuda S, et al. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol. 2014;49:1495-1503.
Kurosaki M, Izumi N. External validation of FIB-4: diagnostic accuracy is limited in elderly populations. Hepatology. 2008;47:352-353.
Tamaki N, Higuchi M, Kurosaki M, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Sci Rep. 2019;9:10109.
Ishiba H, Sumida Y, Tanaka S, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018;53:1216-1224.
Sporea I, Lupușoru R, Mare R, et al. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment. J Gastrointestin Liver Dis. 2017;26:145-150.
Stasi C, Arena U, Zignego AL, et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis. 2013;45:840-843.
Calvaruso V, Di Marco V, Ferraro D, et al. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon. 2013:13.e7176.
D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59:251-256.
Bachofner JA, Valli PV, Kröger A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37:369-376.
Kawagishi N, Suda G, Kimura M, et al. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 2020;50:671-681.
Seko Y, Moriguchi M, Hara T, et al. Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. Hepatol Res. 2019;49:473-478.
Pellicoro A, Aucott RL, Ramachandran P, et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology. 2012;55:1965-1975.
Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res. 2014;107:23-30.
Yasui Y, Abe T, Kurosaki M, et al. Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatol Res. 2019;49:33-41.